• Please contact us if you are experiencing difficulty downloading graphics - LiveChat or helpdesk@graphicnews.com
  • For full details of graphics available/in preparation, see Menu -> Planners
 La distribución lenta de vacunas Covid-19 de la UE infographic
El grafico muestra la cronología de obtención y aprobación de múltiples vacunas Covid-19 en la UE y el RU.
GN41012ES

SALUD

Enfoque vacilante de vacunación Covid-19 de la UE

By Ninian Carter

February 3, 2021 - El manejo torpe de la vacunación contra Covid-19 de la Unión Europea se origina en las fechas de los pedidos a las compañías farmacéuticas y las fechas en que se otorgó la aprobación para el uso de las vacunas.

The European Union's Covid-19 vaccination programme is struggling to get its hands on enough vaccine – trailing countries like Israel, the UK and United States. Worryingly, there seems no sign of the vaccination rate increasing anytime soon, unlike the UK, where rates have increased markedly in recent days.

A key failure is that the EU simply ordered too few vaccines too late. For example, it was too slow to order the Pfizer/BioNTech vaccine, even after it became the frontrunner, and member states hesitated to ask the EU to order more.

Drug purchases were further delayed by disagreements over liability in case of negative side-effects on health from the vaccines, with the EU pushing for it to rest with pharmaceutical companies. This led to the rejection of early emergency authorisations as many EU member states were averse to such risks. European anti-vaccination movements may have compounded the pressures on politicians too.

The EU, with a population of nearly 450 million people, also found its funding wanting. Last year, it allocated €3.79 billion ($4.56 billion) for advance purchase agreements. By comparison, the U.S., with a lesser population of under 330 million people, pledged $18 billion.

The EU also chose to bargain with Big Pharma to achieve lower purchases prices, as if it had plenty of time on its hands, whereas other nations acted to expedite huge orders.

Further adding to the disarray is the EU's slow speed to develop a strategy to increase production. More factories could have been mobilised as soon as possible to increase the total supply of vaccines, instead of waiting until this year to do so.

A recent furious spat with the UK has fuelled debate that the makers of the AstraZeneca vaccine may be breaching the terms of its contract with the EU, by not supplying enough vaccines to the bloc while maintaining good deliveries to the UK. But as the AstraZeneca CEO points out, the UK signed its contract three months before the EU and the UK factory also started operating earlier, increasing its capacity to supply.

Sources
PUBLISHED: 03/02/2021; STORY: Graphic News; PICTURES: Getty Images
Advertisement